Product Description
Mechanisms of Action: ADRB2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Inhalant, Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Argentina | Austria | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Czech | Denmark | Dominican Republic | Egypt | Estonia | Finland | France | Germany | Greece | Hungary | Indonesia | Ireland | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/26/2023 |
News Article |
Magnesium Matrix Fire Rated Boards Market Upcoming Outlook 2023-2030 |